Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 770,100 shares, an increase of 307.9% from the March 15th total of 188,800 shares. Currently, 19.3% of the company’s stock are short sold. Based on an average daily volume of 1,560,000 shares, the days-to-cover ratio is presently 0.5 days.

Dermata Therapeutics Stock Down 8.8 %

Dermata Therapeutics stock opened at $0.71 on Thursday. The stock’s 50 day moving average is $1.10 and its 200 day moving average is $1.22. The company has a market capitalization of $3.86 million, a P/E ratio of -0.04 and a beta of 0.58. Dermata Therapeutics has a twelve month low of $0.70 and a twelve month high of $6.17.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.